Critical appraisal of cabazitaxel in the management of advanced prostate cancer - Wikidata - awgldk - TriplyDB

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

http://www.wikidata.org/entity/Q34386577

about

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.Castration-resistant prostate cancer: mechanisms, targets, and treatment.Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer Update on taxane development: new analogs and new formulations The changing landscape in the treatment of metastatic castration-resistant prostate cancer.Senior adult oncology.Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects.Current treatment strategies for castration-resistant prostate cancer Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.Therapeutic options for advanced prostate cancer: 2011 update.Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.

P2860

Q34712333-774D6CA4-FEE2-437D-B16C-604CA0BA4FA6 Q35600421-1E8F503E-386D-4898-9549-A91655499FB1 Q35864027-CE809B77-7961-4CCE-9167-037C7C60FB09 Q36253388-50AB3A85-9A35-406D-9CC2-33D8B0080460 Q36327344-41862158-7BBF-4CD7-AEC2-B3073DCC76C9 Q36470377-4B8CA09E-1050-4866-B4FA-B52AA930EAEC Q36515526-86644CD2-C376-417B-AF26-511491C78E2D Q36851424-B86B8B38-6F1B-4AE1-B3A9-6D9618E3EBF3 Q37303584-520357A1-0800-4759-9589-2E015FFB7E8F Q37860950-14669E00-18EA-485A-875A-647927F3738A Q37988590-F871C47A-E32A-49E6-8A5C-2E0BFCB69E98 Q37989011-50E66337-839B-4E34-9F35-DD44B5506629 Q38244522-764410ED-46B7-4C6B-BA65-ABE68A8519E0 Q38546598-C2E3CACB-6B24-4E7E-B4AD-69A19F393A8E

P2860

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

http://www.wikidata.org/entity/Q34386577

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@ast

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@en

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@nl

type

label

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@ast

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@en

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@nl

prefLabel

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@ast

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@en

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@nl

P1433

Q34386577-523902AD-2B24-4C3B-BF76-EC43FDD28769

P1476

Q34386577-44604970-1C67-4E42-8EAF-890A62404B32

P2093

Q34386577-3E803FC5-CE62-4925-A0B0-54A9676C135E

Q34386577-5111354D-2CE4-4DDB-8C7A-26845C0ACC0F

Q34386577-BF21E23E-B3ED-42F1-9FE3-1718B4E30A73

P2860

Q34386577-0A6FDF8F-F59E-4A4C-9855-C84A9507D8A8

Q34386577-21B1BCC6-EDD2-4703-BDBE-0B3DE03F7855

Q34386577-2B05FD6C-E705-40E2-A18E-A93F0914062A

Q34386577-3F67A080-932F-42BE-8B7D-ED7A3E567C43

Q34386577-44602776-4EE9-4473-B699-8EE5109CEA8C

Q34386577-46680B5C-9266-4A21-A606-C4BA0A55A568

Q34386577-4D3D6DA7-F9E3-46F9-A88E-1CED5A036C76

Q34386577-5070D914-B8AB-4B7F-9DA7-B16C36AEDC90

Q34386577-5ACF51BA-285A-46BE-8FE4-DC7E42E318F6

Q34386577-61829E18-92E3-45F6-A7EE-298E5957153E

P304

Q34386577-A7A1A739-CE84-4F67-9FB1-A233F05E453F

P31

Q34386577-488BAFB2-31B9-44DB-B649-E95CFB5462A5

Q34386577-8C8B31F7-08F1-49A9-A70A-B5E1E66B9396

P356

Q34386577-AB4EE97F-3FDA-4D74-8600-2E27D46E80B8

P407

Q34386577-E5AD5D3A-C964-4CE5-BE8F-6135D7D52F6F

P478

Q34386577-07D39211-73C7-43FB-823C-038A855170E7

P577

Q34386577-349149C7-2E83-439F-8965-14ED7A088FDE

P698

Q34386577-C0A3E6A4-334C-4A0C-A9C5-6F22FB016DD0

P921

Q34386577-2DC602AE-0ED9-4C65-9656-E20DB796B151

Q34386577-3A98AB2F-E202-47F3-8BF5-11CBFB0107FD

P932

Q34386577-6AA8A37E-3FBC-4572-86F4-7A914380C4C1

P356

P1433

Clinical Interventions in Aging

P1476

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

@en

P2093

Oliver Sartor

http://www.w3.org/2001/XMLSchema#string

Przemyslaw Twardowski

http://www.w3.org/2001/XMLSchema#string

Sumanta Kumar Pal

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Isolation of a human prostate carcinoma cell line (DU 145).

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

P304

395-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CIA.S14570

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21152241

http://www.w3.org/2001/XMLSchema#string

P921

prostate cancer

P932

2998247

http://www.w3.org/2001/XMLSchema#string